Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
32.28
-1.49 (-4.41%)
At close: Mar 3, 2026, 4:00 PM EST
33.46
+1.18 (3.66%)
Pre-market: Mar 4, 2026, 8:44 AM EST

Teva Pharmaceutical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,418-1,959-615-2,499456
Depreciation & Amortization
1,0021,0591,1531,3081,330
Stock-Based Compensation
157123121124119
Other Adjustments
4382,4597811,302594
Change in Receivables
-17324512--
Changes in Inventories
152166-147--
Changes in Accounts Payable
-152581,588--
Changes in Other Operating Activities
-2,696-1,539-1,5971,355-1,701
Operating Cash Flow
1,6491,2471,3681,590798
Operating Cash Flow Growth
32.24%-8.85%-13.96%99.25%-34.38%
Capital Expenditures
-501-498-526-548-562
Sale of Property, Plant & Equipment
34436868311
Purchases of Investments
-57-71-46-1-47
Proceeds from Sale of Investments
4240-4172
Payments for Business Acquisitions
--15--7-
Other Investing Activities
1,2191,2931,4721,1401,649
Investing Cash Flow
7377929686561,523
Short-Term Debt Issued
--700-700
Short-Term Debt Repaid
---700--700
Long-Term Debt Issued
2,298-2,451-4,974
Long-Term Debt Repaid
-4,112-1,641-4,152-1,369-7,140
Net Long-Term Debt Issued (Repaid)
-1,814-1,641-1,701-1,369-2,166
Other Financing Activities
-337-150-212-118-6
Financing Cash Flow
-2,151-1,791-1,913-1,487-2,172
Effect of Exchange Rate Changes on Cash and Cash Equivalents
21-174-30-123-128
Net Cash Flow
2567439363621
Free Cash Flow
1,1487498421,042236
Free Cash Flow Growth
53.27%-11.04%-19.19%341.52%-63.01%
FCF Margin
6.65%4.53%5.31%6.98%1.49%
Free Cash Flow Per Share
0.990.660.750.940.21
Levered Free Cash Flow
-2,461-3,834-1,789-1,700-2,682
Unlevered Free Cash Flow
416.47-1,017899.14364.62232.73
Updated Jan 28, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q